Bayer AG aims to claim China’s OTC market throne with its recent acquisition of an OTC and traditional Chinese medicine company, but other firms also have their sights set on expanding in the country.
Game Of Thrones: Bayer Looks To Lead China’s OTC Market
The recent acquisition of Dihon Pharmaceutical Group marks progress toward Bayer’s goal of becoming the leader in the OTC sector in China. Dihon provides an entry into the TCM arena, which makes up about half of the OTC segment in China, the firm says.